Breast Cancer
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch
Premium
At ASCO, the company detailed its efforts to make the 93-SNP riskScore, which it plans to offer as a standalone DTC test next year, relevant for women of all ancestries.
Breast Cancer Genomics Study Reveals Recurrent Contributors to Treatment Resistance in Early Disease
Researchers saw convergent subclones crop up in early-stage, estrogen receptor-positive breast cancers that dodged endocrine- and CDK4/6 inhibitor-based therapies.
The proposed change would delete payable cancer codes if they contain the word "unspecified" even if the word is included in a code that doesn't impact coverage.
The talks focused on studies stemming from the Cancer Moonshot initiative's Human Tumor Atlas Network project, which is readying its first data release.